Skip to content
10-Q

Quarterly Report

4D Molecular Therapeutics, Inc. FDMT

0001193125-26-211939

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted Q1 2026 · Mar 31, 2026 68.06M sh
Shares Diluted Q1 2026 · Mar 31, 2025 55.74M sh
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$68.13M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$47.76M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $72.49M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $60.24M
Stockholders Equity Q1 2026 · Mar 31, 2026 $451.84M
Stockholders Equity Q1 2026 · Dec 31, 2025 $505.66M
Stockholders Equity Q1 2026 · Mar 31, 2025 $469.72M
Stockholders Equity Q1 2026 · Dec 31, 2024 $510.61M
Current Liabilities Q1 2026 · Mar 31, 2026 $43.4M
Current Liabilities Q1 2026 · Dec 31, 2025 $43.99M
Total Liabilities Q1 2026 · Mar 31, 2026 $61.07M
Total Liabilities Q1 2026 · Dec 31, 2025 $61.05M
Current Assets Q1 2026 · Mar 31, 2026 $405.36M
Current Assets Q1 2026 · Dec 31, 2025 $413.13M
Total Assets Q1 2026 · Mar 31, 2026 $512.91M
Total Assets Q1 2026 · Dec 31, 2025 $566.71M
Eps Diluted Q1 2026 · Mar 31, 2026 −$1.01
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.86
Eps Basic Q1 2026 · Mar 31, 2026 −$1.01
Eps Basic Q1 2026 · Mar 31, 2025 −$0.86
Sga Expense Q1 2026 · Mar 31, 2026 $11.69M
Sga Expense Q1 2026 · Mar 31, 2025 $12.94M
Net Income Q1 2026 · Mar 31, 2026 −$68.76M
Net Income Q1 2026 · Mar 31, 2025 −$47.97M
Operating Income Q1 2026 · Mar 31, 2026 −$73.62M
Operating Income Q1 2026 · Mar 31, 2025 −$53.62M
Revenue Q1 2026 · Mar 31, 2026 $3.05M
Revenue Q1 2026 · Mar 31, 2025 $14K